...
首页> 外文期刊>British Journal of Haematology >Childhood acute myeloid leukaemia
【24h】

Childhood acute myeloid leukaemia

机译:儿童急性髓性白血病

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Although acute myeloid leukaemia (AML) has long been recognized for its morphological and cytogenetic heterogeneity, recent high-resolution genomic profiling has demonstrated a complexity even greater than previously imagined. This complexity can be seen in the number and diversity of genetic alterations, epigenetic modifications, and characteristics of the leukaemic stem cells. The broad range of abnormalities across different AML subtypes suggests that improvements in clinical outcome will require the development of targeted therapies for each subtype of disease and the design of novel clinical trials to test these strategies. It is highly unlikely that further gains in long-term survival rates will be possible by mere intensification of conventional chemotherapy. In this review, we summarize recent studies that provide new insight into the genetics and biology of AML, discuss risk stratification and therapy for this disease, and profile some of the therapeutic agents currently under investigation.
机译:尽管长期以来,急性髓细胞白血病(AML)因其形态学和细胞遗传学异质性而得到认可,但最近的高分辨率基因组分析已证明其复杂性甚至超过了以前的想象。这种复杂性可以从白血病干细胞的遗传改变,表观遗传修饰和特征的数量和多样性中看出。跨不同AML亚型的广泛异常表明,临床结果的改善将需要针对每种疾病亚型开发靶向治疗,并需要设计新颖的临床试验来测试这些策略。仅通过加强常规化学疗法就不可能进一步提高长期生存率。在这篇综述中,我们总结了最近的研究,这些研究为AML的遗传学和生物学提供了新的见解,讨论了该疾病的风险分层和治疗方法,并对目前正在研究的某些治疗药物进行了概述。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号